Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Understanding the Burden and Post-Discharge Management of Severe Malarial Anaemia and Severe Malaria Among Tanzanian Children: An Epidemiological and Qualitative Study (PODSMA-TZ)

19. listopadu 2026 aktualizováno: Ifakara Health Institute

This study will examine what happens to children aged 3 months to 5 years after hospital discharge following severe malaria or severe malarial anaemia (a very low blood level caused by malaria). It will take place at Newala District Hospital in Tanzania.

Researchers will review hospital records from the previous two years. They will also follow 250 children for 12 weeks after hospital discharge.

The study will examine:

  1. Whether children die or return to hospital after discharge.
  2. Whether children experience malaria again after discharge.
  3. How children's blood levels recover after severe illness.
  4. The healthcare services families use and the costs they face.

Researchers will also interview caregivers, community health workers and healthcare providers. These interviews will explore experiences, challenges and support available to children after hospital discharge.

The findings will help improve understanding of children's recovery after severe malaria. They may also inform future approaches to follow-up care and support for affected children.

This is an observational study. Researchers will not give participants any study medicine or additional treatment.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Detailní popis

PODSMA-TZ is a non-interventional, observational mixed-methods study conducted at Newala District Hospital, Mtwara Region, Tanzania. The study combines retrospective review of routine hospital records, prospective follow-up of children discharged after severe malaria or severe malarial anaemia (SMA), and qualitative research.

The retrospective component will review routinely collected hospital records from the preceding two years. Basic admission information will be abstracted for all children aged 3 months to 5 years to establish the denominator of paediatric admissions. More detailed demographic, clinical, laboratory, treatment and outcome information will be collected for children diagnosed with severe malaria or SMA according to World Health Organization criteria.

The prospective component will involve observational follow-up of eligible children after hospital discharge. Information will be collected on their health and recovery, healthcare utilisation, care-seeking practices and medication adherence. Healthcare-related costs and household expenditures associated with care will also be documented during follow-up.

The qualitative component will explore experiences and challenges associated with post-discharge care. Approximately 30 caregivers will participate in in-depth interviews. An estimated 20-25 healthcare providers will participate in key-informant interviews. Additionally, 4-6 focus group discussions will be conducted with community health workers, with 6-8 participants in each group.

Qualitative discussions will explore experiences of caring for children after severe malaria, barriers and facilitators to accessing follow-up care, malaria prevention practices, and awareness and perceptions of potential future post-discharge malaria chemoprevention (PDMC) and monoclonal antibody interventions. These discussions will also explore acceptability and readiness for possible future implementation of these approaches.

Interviews and focus group discussions will be audio-recorded with participants' consent, transcribed in Kiswahili and translated into English where required.

The study does not involve randomisation, allocation to intervention groups or administration of study treatments. Clinical care will continue according to routine healthcare practice.

Typ studie

Pozorovací

Zápis (Odhadovaný)

250

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Kamaka Ramadhani Kassimu, PhD
  • Telefonní číslo: +255713488238
  • E-mail: kramadhani@ihi.or.tz

Studijní místa

    • Mtwara
      • Newala, Mtwara, Tanzanie, 63422
        • Newala District Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Kamaka R Kassimu, PhD
        • Dílčí vyšetřovatel:
          • Scolastica L Lusenge, MD
        • Dílčí vyšetřovatel:
          • Tunu H Ndanzi, Msc.
        • Dílčí vyšetřovatel:
          • Abdallah S Lusasi, MPH
        • Dílčí vyšetřovatel:
          • Hassan T Berenge, MA (PME)

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

3 měsíce až 5 let (Dítě)

Přijímá zdravé dobrovolníky

N/A

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Children aged 3 months to 5 years admitted with severe malaria or SMA at Newala District Hospital and followed after discharge; paediatric hospital admission records for the two-year retrospective review; and caregivers, healthcare providers and community health workers involved in post-discharge care in Newala District.

Popis

Eligibility - Retrospective

Inclusion Criteria:

  • All paediatric admissions aged 3 months to 5 years during the two-year review period contribute basic admission information; detailed clinical abstraction for records of children diagnosed with severe malaria or SMA according to WHO criteria.

Exclusion Criteria:

  • Records outside age range; insufficient information to determine eligibility, diagnosis or outcome; inadequate documentation to confirm severe malaria or SMA. Eligibility - Prospective Cohort

Inclusion criteria:

- Child aged 3 months to 5 years; admitted with severe malaria or SMA; clinically stable for discharge; parent/legal guardian provides written informed consent.

Exclusion criteria:

  • Declined/no consent; prior enrolment in prospective cohort; known chronic conditions requiring long-term specialised care (e.g., malignancy or severe congenital disease requiring tertiary management). Common co-existing conditions including severe acute malnutrition, HIV, sickle cell disease, pneumonia and sepsis are not exclusion criteria. Eligibility - Qualitative
  • Caregivers of enrolled children, healthcare providers and community health workers. Participation is voluntary; individuals who decline or are unable to participate in Kiswahili without translation support are excluded.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: OTHER
  • Časové perspektivy: OTHER

Kohorty a intervence

Skupina / kohorta
Children discharged after severe malaria or severe malarial anaemia (prospective cohort).

Approximately 250 children aged 3 months to 5 years admitted with severe malaria or SMA, clinically stable for discharge and enrolled at discharge following written guardian consent. Follow-up at Weeks 1, 4, 8 and 12. No intervention or assigned exposure.

Retrospective paediatric hospital records

Routinely collected records of all children aged 3 months to 5 years admitted during the preceding two-year review period provide denominator data. Detailed abstraction is undertaken for records of children diagnosed with severe malaria or SMA according to WHO criteria. This is a records-based component, not an intervention group.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
All-cause post-discharge mortality.
Časové okno: Day 0 through Day 84 after discharge/enrolment.

Death from any cause during the 12-week post-discharge period, reported as the proportion of enrolled children who die. Day 0 is discharge/enrolment.

Day 0 through Day 84 after discharge/enrolment.
Hospital readmission
Časové okno: Day 0 through Day 84

One or more overnight rehospitalisations for any cause during the 12-week follow-up. Summarise the proportion with any readmission and total number of readmissions

Day 0 through Day 84
Recurrent clinical malaria
Časové okno: Day 0 through Day 84

Time to first recurrent malaria episode, defined as a positive malaria RDT or microscopy result accompanied by fever or history of fever

Day 0 through Day 84
Anaemia recovery among children with SMA at baseline.
Časové okno: Week 12 assessment; permitted visit window up to 7 days after Day 84 (Days 85-91).

Achievement of haemoglobin concentration ≥10 g/dL at the Week 12 assessment among participants with SMA at baseline.

Week 12 assessment; permitted visit window up to 7 days after Day 84 (Days 85-91).
Haemoglobin trajectory
Časové okno: Baseline/discharge through Weeks 1, 4, 8 and 12; Week 12 may occur within the permitted +7-day window.

Change in haemoglobin concentration across baseline and follow-up assessments. Baseline haemoglobin is the admission measurement if available; otherwise, the discharge/enrolment measurement is used.

Baseline/discharge through Weeks 1, 4, 8 and 12; Week 12 may occur within the permitted +7-day window.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Epidemiological and clinical patterns of severe malaria and severe malarial anaemia.
Časové okno: Retrospective two-year record review; prospective admission through discharge for clinical/in-hospital outcomes, with post-discharge healthcare utilisation and costs assessed through Day 84 (12 weeks).

Distribution of admissions by age, sex and geographical origin; clinical/laboratory characteristics; parasite density where available; comorbidities; monthly and seasonal trends; and in-hospital outcomes. Healthcare utilisation and direct post-discharge healthcare costs will also be summarised.

Retrospective two-year record review; prospective admission through discharge for clinical/in-hospital outcomes, with post-discharge healthcare utilisation and costs assessed through Day 84 (12 weeks).

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

31. března 2027

Primární dokončení (Odhadovaný)

30. června 2028

Dokončení studie (Odhadovaný)

30. června 2028

Termíny zápisu do studia

První předloženo

12. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

19. listopadu 2026

První zveřejněno (Aktuální)

20. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

20. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

19. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 23540
  • 337563 (Jiné číslo grantu/financování: GSK African Open Lab)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NEROZHODNÝ

Popis plánu IPD

To be confirmed by sponsor and PI. Protocol allows de-identified data sharing subject to institutional and applicable data-protection requirements but does not specify a formal public IPD-sharing commitment.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .